Jasper Therapeutics (JSPR) Competitors $21.57 +0.04 (+0.19%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends JSPR vs. SYRE, CALT, SPRY, SNDX, ANIP, RCKT, BCYC, AVDL, COLL, and SEPNShould you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include Spyre Therapeutics (SYRE), Calliditas Therapeutics AB (publ) (CALT), ARS Pharmaceuticals (SPRY), Syndax Pharmaceuticals (SNDX), ANI Pharmaceuticals (ANIP), Rocket Pharmaceuticals (RCKT), Bicycle Therapeutics (BCYC), Avadel Pharmaceuticals (AVDL), Collegium Pharmaceutical (COLL), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry. Jasper Therapeutics vs. Spyre Therapeutics Calliditas Therapeutics AB (publ) ARS Pharmaceuticals Syndax Pharmaceuticals ANI Pharmaceuticals Rocket Pharmaceuticals Bicycle Therapeutics Avadel Pharmaceuticals Collegium Pharmaceutical Septerna Spyre Therapeutics (NASDAQ:SYRE) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, community ranking, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Do institutionals & insiders believe in SYRE or JSPR? 80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 79.8% of Jasper Therapeutics shares are owned by institutional investors. 6.2% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor SYRE or JSPR? Jasper Therapeutics received 24 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 88.89% of users gave Jasper Therapeutics an outperform vote. CompanyUnderperformOutperformSpyre TherapeuticsOutperform Votes16100.00% Underperform VotesNo VotesJasper TherapeuticsOutperform Votes4088.89% Underperform Votes511.11% Do analysts recommend SYRE or JSPR? Spyre Therapeutics currently has a consensus price target of $51.50, suggesting a potential upside of 115.84%. Jasper Therapeutics has a consensus price target of $73.38, suggesting a potential upside of 240.17%. Given Jasper Therapeutics' higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than Spyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Jasper Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, SYRE or JSPR? Spyre Therapeutics has a beta of 2.82, indicating that its share price is 182% more volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Which has stronger earnings & valuation, SYRE or JSPR? Jasper Therapeutics has lower revenue, but higher earnings than Spyre Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre Therapeutics$890K1,378.81-$338.79M-$7.47-3.19Jasper TherapeuticsN/AN/A-$64.46M-$4.74-4.55 Is SYRE or JSPR more profitable? Jasper Therapeutics' return on equity of -67.64% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -210.01% -44.40% Jasper Therapeutics N/A -67.64%-58.53% Does the media prefer SYRE or JSPR? In the previous week, Spyre Therapeutics had 3 more articles in the media than Jasper Therapeutics. MarketBeat recorded 5 mentions for Spyre Therapeutics and 2 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 1.79 beat Spyre Therapeutics' score of 0.42 indicating that Jasper Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jasper Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummarySpyre Therapeutics beats Jasper Therapeutics on 8 of the 15 factors compared between the two stocks. Ad ProsperityPubThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JSPR vs. The Competition Export to ExcelMetricJasper TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$323.57M$2.94B$5.13B$9.07BDividend YieldN/A1.90%5.08%4.23%P/E Ratio-4.5546.7389.7417.18Price / SalesN/A415.011,116.12116.95Price / CashN/A182.1042.8237.86Price / Book3.073.894.774.78Net Income-$64.46M-$42.21M$120.15M$225.60M7 Day Performance4.71%-2.15%-1.92%-1.23%1 Month Performance-1.24%4.20%11.47%3.36%1 Year Performance287.74%18.39%30.52%16.60% Jasper Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JSPRJasper Therapeutics2.3297 of 5 stars$21.57+0.2%$73.38+240.2%+290.1%$323.57MN/A-4.5520Positive NewsSYRESpyre Therapeutics1.765 of 5 stars$24.71+2.4%$51.50+108.4%+53.4%$1.27B$890,000.00-3.23100CALTCalliditas Therapeutics AB (publ)0.065 of 5 stars$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180SPRYARS Pharmaceuticals3.1441 of 5 stars$12.22+2.7%$24.00+96.4%+121.8%$1.19B$30,000.00-23.3390Insider TradeNews CoverageSNDXSyndax Pharmaceuticals3.952 of 5 stars$13.74-1.4%$37.64+173.9%-33.6%$1.17B$16M-3.84110News CoverageANIPANI Pharmaceuticals4.836 of 5 stars$55.77-1.4%$77.71+39.3%+1.9%$1.17B$555.46M-102.89642Insider TradeRCKTRocket Pharmaceuticals4.8477 of 5 stars$11.99-0.2%$51.00+325.4%-58.6%$1.09BN/A-4.37240Analyst ForecastBCYCBicycle Therapeutics3.6084 of 5 stars$15.47+12.0%$36.00+132.7%-18.8%$1.07B$26.98M-4.56240Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading VolumeAVDLAvadel Pharmaceuticals2.6635 of 5 stars$10.96+5.5%$24.43+122.9%-24.0%$1.06B$138.16M-13.15154Positive NewsCOLLCollegium Pharmaceutical3.8414 of 5 stars$30.65+1.9%$42.60+39.0%-0.4%$988.46M$599.25M12.97210News CoveragePositive NewsSEPNSepterna2.2189 of 5 stars$21.81-2.6%$43.67+100.2%N/A$968.36MN/A0.00N/A Related Companies and Tools Related Companies Spyre Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives ARS Pharmaceuticals Alternatives Syndax Pharmaceuticals Alternatives ANI Pharmaceuticals Alternatives Rocket Pharmaceuticals Alternatives Bicycle Therapeutics Alternatives Avadel Pharmaceuticals Alternatives Collegium Pharmaceutical Alternatives Septerna Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:JSPR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
